清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial

医学 内科学 安慰剂 胃肠病学 聚乙二醇干扰素α-2a 临床终点 肝病学 乙型肝炎表面抗原 随机对照试验 慢性肝炎 免疫学 病毒 利巴韦林 乙型肝炎病毒 病理 替代医学
作者
Heiner Wedemeyer,Cihan Yurdaydın,Svenja Hardtke,Florin Alexandru Căruntu,Manuela Curescu,Kendal Yalçın,Ulus Salih Akarca,Selım Gürel,Stefan Zeuzem,Andreas Erhardt,Stefan Lüth,George Papatheodoridis,Onur Keskın,Kerstin Port,Monica Radu,Mustafa Kemal Çelen,Ramazan İdilman,Kristina Weber,Judith Stift,Ulrike Wittkop,Benjamin Heidrich,Ingmar Mederacke,Heiko von der Leyen,Hans Peter Dienes,Markus Cornberg,Armin Koch,Michael P. Manns
出处
期刊:Lancet Infectious Diseases [Elsevier]
卷期号:19 (3): 275-286 被引量:144
标识
DOI:10.1016/s1473-3099(18)30663-7
摘要

Background Hepatitis D is the most severe form of chronic viral hepatitis. Treatment guidelines recommend 1 year of peginterferon alfa, which is effective in 25–30% of patients only. Whether prolonged therapy with peginterferon alfa-2a for 96 weeks and combination therapy with tenofovir disoproxil fumarate (TDF) would increase hepatitis D virus (HDV) RNA suppression is unknown. We aimed to explore whether prolonged treatment of HDV with 96 weeks of peginterferon would increase HDV RNA response rates and reduces post-treatment relapses. Methods We did two parallel, investigator-initiated, multicentre, double-blind randomised, controlled trials at 14 study sites in Germany, Greece, Romania, and Turkey. Patients with chronic HDV infection and compensated liver disease who were aged 18 years or older were eligible for inclusion. All patients were HBsAg positive for at least 7 months, anti-HDV positive for at least 3 months, and HDV-RNA positive at the local laboratory at the screening visit. Patients were ineligible if alanine aminotransferase levels were higher than ten times above the upper limit of normal and if platelet counts were lower than 90 000 per μL, or if they had received interferon therapy or treatment with a nucleoside and nucleotide analogue within the preceding 6 months. Patients were randomly assigned by blinded stratified block randomisation (1:1) to receive 180 μg of peginterferon alfa-2a weekly plus either TDF (300 mg once daily) or placebo for 96 weeks. The primary endpoint was the percentage of patients with undetectable HDV RNA at the end of treatment assessed by intention to treat. The trials are registered as NCT00932971 and NCT01088659. Findings Between June 24, 2009, and Feb 28, 2011, we randomly assigned 59 HDV RNA-positive patients to receive peginterferon alfa-2a plus TDF and 61 to receive peginterferon alfa-2a plus placebo, including 48 (40%) patients with cirrhosis to the two treatment groups (23 in the peginterferon alfa-2a plus TDF group and 25 in the peginterferon alfa-2a plus placebo group). The primary endpoint was achieved in 28 (48%) of 59 patients in the peginterferon alfa-2a plus TDF group and in 20 (33%) of 61 patients in the peginterferon alfa-2a plus placebo group (odds ratio 1·84, 95% CI 0·86–3·91, p=0·12). We recorded 944 adverse events (459 in the peginterferon alfa-2a plus TDF group and 485 in the peginterferon alfa-2a plus placebo group). The most common adverse events were haematological, behavioural (eg, fatigue), musculoskeletal, influenza-like syndromes, and psychiatric complaints. Interpretation Addition of TDF resulted in no significant improvement in HDV RNA response rates at the end of treatment. These findings highlight that alternative treatment options are needed for hepatitis D. Funding The HepNet Study-House (a project of the German Liver Foundation founded by the German Liver Foundation, the German Ministry for Education and Research, and the German Center for Infectious Disease Research), Hoffmann-La Roche, and Gilead Sciences.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助科研通管家采纳,获得10
10秒前
小西完成签到 ,获得积分10
27秒前
wodetaiyangLLL完成签到 ,获得积分10
50秒前
gszy1975完成签到,获得积分10
1分钟前
orixero应助科研通管家采纳,获得10
2分钟前
yujie完成签到 ,获得积分10
2分钟前
新八完成签到,获得积分10
3分钟前
3分钟前
睡不醒也吃不饱完成签到 ,获得积分10
3分钟前
silence发布了新的文献求助30
3分钟前
3分钟前
LiXingchen发布了新的文献求助50
3分钟前
silence完成签到,获得积分10
4分钟前
LiXingchen完成签到,获得积分10
4分钟前
哈哈完成签到 ,获得积分10
4分钟前
lanxinge完成签到 ,获得积分10
4分钟前
魔幻的妖丽完成签到 ,获得积分10
4分钟前
专注半烟完成签到 ,获得积分10
5分钟前
无悔完成签到 ,获得积分10
5分钟前
meini完成签到 ,获得积分10
6分钟前
搜集达人应助科研通管家采纳,获得10
6分钟前
我是老大应助葛力采纳,获得10
6分钟前
dream完成签到 ,获得积分10
6分钟前
7分钟前
额狐狸发布了新的文献求助10
7分钟前
不甜的唐完成签到,获得积分10
8分钟前
大脸猫完成签到 ,获得积分10
9分钟前
9分钟前
不甜的唐发布了新的文献求助10
10分钟前
拼搏问薇完成签到 ,获得积分10
11分钟前
Yau完成签到,获得积分10
11分钟前
刘刘完成签到 ,获得积分10
11分钟前
李志全完成签到 ,获得积分10
12分钟前
12分钟前
summer完成签到,获得积分10
12分钟前
唯12345发布了新的文献求助10
12分钟前
Ryoman完成签到,获得积分10
12分钟前
小布完成签到 ,获得积分10
13分钟前
zhengzhster应助唯12345采纳,获得10
13分钟前
lixuebin完成签到 ,获得积分10
14分钟前
高分求助中
The ACS Guide to Scholarly Communication 2500
Microlepidoptera Palaearctica, Volumes 1 and 3 - 13 (12-Volume Set) [German] 1122
Subjective Well-Being and Life Satisfaction (第二版) 1000
The Data Economy: Tools and Applications 1000
PraxisRatgeber Mantiden., faszinierende Lauerjäger. – Buch gebraucht kaufen 700
Mantiden - Faszinierende Lauerjäger – Buch gebraucht kaufen 700
Ожившие листья и блуждающие цветы. Практическое руководство по содержанию богомолов [Alive leaves and wandering flowers. A practical guide for keeping praying mantises] 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3095207
求助须知:如何正确求助?哪些是违规求助? 2747134
关于积分的说明 7592921
捐赠科研通 2398710
什么是DOI,文献DOI怎么找? 1272675
科研通“疑难数据库(出版商)”最低求助积分说明 615427
版权声明 598928